International Assets Investment Management LLC Buys Shares of 154,464 Progyny, Inc. $PGNY

Key Points

• International Assets Investment Management LLC acquired 154,464 shares of Progyny, Inc., valued at approximately $3.4 million, representing 0.18% ownership of the company.
• Progyny reported earnings of $0.19 per share for the latest quarter, missing estimates by $0.23, although revenue grew by 9.5% year-over-year to $332.87 million.
• Analysts have set new price targets for Progyny, with Cantor Fitzgerald and JPMorgan Chase raising their targets to $28.00 and $25.00, respectively, indicating strong market interest in the stock.

International Assets Investment Management LLC bought a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 154,464 shares of the company's stock, valued at approximately $3,398,000. International Assets Investment Management LLC owned approximately 0.18% of Progyny as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Progyny during the 2nd quarter valued at $433,000. Nordea Investment Management AB raised its position in shares of Progyny by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company's stock worth $4,052,000 after acquiring an additional 1,140 shares in the last quarter. Truist Financial Corp raised its position in shares of Progyny by 47.0% in the 2nd quarter. Truist Financial Corp now owns 23,470 shares of the company's stock worth $516,000 after acquiring an additional 7,499 shares in the last quarter. GC Wealth Management RIA LLC bought a new position in shares of Progyny in the 2nd quarter worth $647,000. Finally, State of Alaska Department of Revenue raised its position in shares of Progyny by 8.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 44,425 shares of the company's stock worth $976,000 after acquiring an additional 3,376 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Insider Transactions at Progyny

In other news, Director Kevin K. Gordon sold 2,500 shares of the company's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the company's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the sale, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,895 shares of company stock worth $179,311 in the last 90 days. Company insiders own 9.40% of the company's stock.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $19.34 on Friday. The business's 50-day moving average is $22.02 and its 200 day moving average is $22.13. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $26.76. The firm has a market capitalization of $1.66 billion, a P/E ratio of 32.78, a P/E/G ratio of 1.64 and a beta of 1.34.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. During the same period in the prior year, the company earned $0.17 earnings per share. The company's quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on PGNY. Raymond James Financial set a $28.00 price target on Progyny in a research report on Friday, August 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Progyny in a research report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price target on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 26th. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Finally, Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target for the company in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.44.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.